ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma PharmaSources/Yefenghong
July 03, 2019The news widespread in the industry that Hengrui has received the pharmaceutical product registration approval for its anti-PD-1 camrelizumab has been confirmed recently. It took 24 days from the beginning of review to the receipt of approval on May 29.
Pharma Sources Insight January 2025
